Kraematon Investment Advisors’s AbbVie ABBV Stock Holding History

Kraematon Investment Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$459K	Sell	1,824 -22	-1%	-$4.73K	0.34%	72
2026 Q1	$402K	Buy	1,846 +2	+0.1%	+$444	0.33%	75
2025 Q4	$421K	Buy	1,844 +2	+0.1%	+$456	0.34%	69
2025 Q3	$426K	Buy	1,842 +3	+0.2%	+$611	0.36%	65
2025 Q2	$341K	Buy	1,839 +3	+0.2%	+$558	0.32%	69
2025 Q1	$385K	Buy	1,836 +2	+0.1%	+$389	0.39%	62
2024 Q4	$326K	Buy	1,834 +3	+0.2%	+$552	0.32%	65
2024 Q3	$362K	Buy	1,831 +3	+0.2%	+$560	0.35%	62
2024 Q2	$314K	Buy	1,828 +3	+0.2%	+$497	0.32%	66
2024 Q1	$332K	Sell	1,825 -32	-2%	-$5.51K	0.33%	66
2023 Q4	$288K	Buy	1,857 +3	+0.2%	+$437	0.32%	69
2023 Q3	$276K	Buy	1,854 +3	+0.2%	+$440	0.34%	65
2023 Q2	$249K	Buy	1,851 +4	+0.2%	+$587	0.27%	72
2023 Q1	$294K	Buy	1,847 +3	+0.2%	+$459	0.34%	65
2022 Q4	$298K	Sell	1,844 -122	-6%	-$18.7K	0.32%	67
2022 Q3	$264K	Sell	1,966 -27	-1%	-$3.87K	0.34%	70
2022 Q2	$305K	Buy	1,993 +56	+3%	+$8.56K	0.35%	63
2022 Q1	$314K	Buy	1,937 +3	+0.2%	+$436	0.3%	70
2021 Q4	$262K	Buy	+1,934	New	+$228K	0.23%	81

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kraematon Investment Advisors's ABBV Position: Q2 2026 in Review

Kraematon Investment Advisors reduced its AbbVie (ABBV) stake by 1.2% in Q2 2026, selling an estimated $4.73K and leaving 1,824 shares worth $459K. The position accounts for 0.34% of the portfolio, ranked #72.

Kraematon Investment Advisors first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Kraematon Investment Advisors held 1,824 shares of AbbVie worth $459K as of Q2 2026.
Kraematon Investment Advisors sold 22 AbbVie shares in Q2 2026, an estimated $4.73K.
AbbVie made up 0.34% of Kraematon Investment Advisors's portfolio in Q2 2026, its #72 holding.
Kraematon Investment Advisors first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kraematon Investment Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.